A domestic bio company has secured global exclusive rights to a novel drug candidate for epilepsy, along with the related development platform, as it moves to strengthen its central nervous system (CNS) drug business. The adoption of a late-stage clinical candidate is a positive development, as it can shorten development timelines and expand business domains. However, the need to pay upfront licensing fees and clinical trial costs may impact short-term cash flow.


As a result, while investors are optimistic about the potential to expand the novel drug pipeline, they remain cautious regarding clinical success and capital burden. Even at advanced clinical stages, several processes remain, including validation of efficacy and safety, and obtaining approval from regulatory authorities. The outcome of these factors can significantly affect the company's valuation. If investors have already used margin or credit transactions, it is important not to increase investment amount based solely on expectations. Instead, they should review collateral maintenance requirements and repayment schedules, and, if necessary, use refinancing to adjust financial costs and capital management periods.


Accordingly, Allnew Stock Loan is attracting attention by offering a range of interest rate options and product configurations, including products with annual interest rates in the 5 percent range. In a rapidly changing market environment, it provides investment options for investors seeking to secure opportunities while managing financial burdens.

Expectations and Costs Collide Over Introduction of New Drug Candidate... Key Factors to Check Before Investing View original image

◆ Allnew Stock Loan: Launch of Lowest Annual Interest Rate Products in the 5% Range!

Allnew Stock Loan has launched a securities-linked credit product with the industry’s lowest annual interest rate in the 5% range, allowing investors to experience stock loans without financial strain. Not only can it be used for stock purchases, but it also enables refinancing of margin/credit transactions from securities firms, with up to four times leverage including one’s own capital, regardless of credit rating. Investors currently using the alternative exchange (NXT) can also take advantage of this service.


For investors seeking more information on Allnew Stock Loan, you can conveniently consult with a professional advisor at the Customer Service Center (☎1599-8666), regardless of your loan status.


○ Launch of industry’s lowest annual interest rate products in the 5% range!

○ ETF trading available

○ Up to four times leverage available for stock funds (including your own capital)!

○ Same-day, immediate refinancing of margin/credit positions from securities firms!

○ Alternative exchange (NXT) trading available

○ Even stocks that were previously difficult to buy with securities firm credit or stock loans are now OK!

* Allnew Stock Loan Customer Service Center: 1599-8666

Direct link: https://allnewstockloan.co.kr


Samsung Electronics Preferred, Korea Electric Power Corporation, Hanwha Ocean, SAMSUNG E&A, Korea Power Engineering



※ This content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing